Subscribe To
CTLT / Catalent (CTLT) New Launch to Aid TPD Programs, Clinical Trials
CTLT News
By Seeking Alpha
October 4, 2023
Catalent Remains Overvalued
Catalent, Inc.'s revenue and scale have suffered due to the decline in vaccine deliveries, particularly in its Biologics segment. The company reported more_horizontal
By Zacks Investment Research
September 27, 2023
3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio
Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock. more_horizontal
By CNBC
September 16, 2023
Activist Elliott makes inroads at Catalent to build value. Here's what could happen next
Elliott recently entered a cooperation agreement with Catalent. This could pave the way for some major changes at the pharmaceutical company. more_horizontal
By Market Watch
September 15, 2023
Catalent gets NYSE notice that it's not in compliance with listing rules over late 10-K filing
Drug manufacturer Catalent Inc. CTLT, +1.74% said Friday it has received a notice from the New York Stock Exchange informing it that's it's not in com more_horizontal
By The Motley Fool
September 1, 2023
Why Catalent Stock Zoomed 12% Higher This Week
The company delivered a better-than-expected quarterly earnings report. It beat on revenue, and only narrowly missed on earnings. more_horizontal
By Zacks Investment Research
August 30, 2023
Catalent (CTLT) Gains Post Deal With Elliott and Earnings Report
Catalent's (CTLT) deal with Elliott and earnings report boost its shares. The company will likely improve its value and growth with the agreement and more_horizontal
By The Motley Fool
August 29, 2023
Why Catalent Stock Surged Nearly 5% Higher Today
The contract drug manufacturer posted steep declines in key fundamentals in its fiscal fourth quarter. Still, it booked more revenue than analysts exp more_horizontal
By Seeking Alpha
August 29, 2023
Catalent, Inc. (CTLT) Q4 2023 Earnings Call Transcript
Catalent, Inc. (NYSE:CTLT ) Q4 2023 Earnings Conference Call August 29, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Re more_horizontal